Page last updated: 2024-11-03

pyrimethamine and Tuberculosis, Multidrug-Resistant

pyrimethamine has been researched along with Tuberculosis, Multidrug-Resistant in 1 studies

Maloprim: contains above 2 cpds

Tuberculosis, Multidrug-Resistant: Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Santivañez-Veliz, M1
Pérez-Silanes, S1
Torres, E1
Moreno-Viguri, E1

Other Studies

1 other study available for pyrimethamine and Tuberculosis, Multidrug-Resistant

ArticleYear
Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.
    Bioorganic & medicinal chemistry letters, 2016, May-01, Volume: 26, Issue:9

    Topics: Animals; Antitubercular Agents; Cell Line; Cyclic N-Oxides; Drug Resistance, Multiple, Bacterial; La

2016